Skip to main content
. Author manuscript; available in PMC: 2010 Jul 6.
Published in final edited form as: Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):554–560. doi: 10.1002/ajmg.b.31019

TABLE II.

Comparison of Response Rates Between the Present Results and Those of Binder et al. [2004] at 2-Week Time Point

Responder
Percent responder Non-responder
Percent non-responder
CC CA AA CC CA AA P-value
rs3800373
    Combined 9% (11) 45% (56) 46% (57) 60% (124) 9% (7) 52% (42) 40% (32) 40% (81) 0.627
    Mirtazipine 6% (4) 49% (34) 46% (32) 63% (70) 12% (5) 59% (24) 29% (12) 37% (41) 0.166
    Paroxetine 13% (7) 41% (22) 46% (25) 57% (54) 5% (2) 45% (18) 50% (20) 43% (40) 0.430
    Max-Planck Institute of Psychiatry 14% (21) 33% (48) 53% (77) 63% (146) 0% (0) 41% (35) 59% (51) 37% (86) 0.00003
    Ludwig Maximillian University 9% (4) 53% (23) 37% (16) 51% (43) 2% (1) 36% (15) 62% (26) 49% (42) 0.053
Responder
Percent responder Non-responder
Percent non-responder
TT CT CC TT CT CC P value
rsl360780
    Combined 8% (10) 48% (60) 44% (54) 60% (124) 12% (10) 51% (41) 37% (30) 40% (81) 0.478
    Mirtazipine 4% (3) 53% (37) 43% (30) 63% (70) 15% (6) 61% (25) 24% (10) 37% (41) 0.046
    Paroxetine 13% (7) 43% (23) 44% (24) 57% (54) 10% (4) 40% (16) 50% (20) 43% (40) 0.835
    Max-Planck Institute of Psychiatry 15% (22) 34% (50) 51% (75) 63% (147) 1% (1) 42% (36) 57% (49) 37% (86) 0.00048
    Ludwig Maximillian University 12% (5) 56% (24) 33% (14) 50% (43) 5% (2) 37% (16) 58% (25) 50% (43) 0.02

Response is defined as a 25% reduction in HDRS-21 score. Results are given as percent responder or non-responder across rows, with the number of genotype carriers shown in parentheses. Binder et al. [2004] results are indicated by rows labeled as Max-Planck, Institute of Psychiatry, and Ludwig Maximillian University. The format of this table is modeled after that of Binder et al. [2004].

HHS Vulnerability Disclosure